InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast
November 24, 2020

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,” Sapirstein stated in the interview. “The market for this particular product, in chronic pancreatitis, competing against pancreatic enzyme replacement therapy (‘PERT’), is about $1 billion outside of the United States and several hundred million dollars inside the United States. The other market is cystic fibrosis. It’s over a $2 billion market worldwide for PERT.”

To view the full press release, visit https://ibn.fm/ahwYW

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).